Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Musculo-skeletal cancers
    • Clinical Trials
    • Illuccix® & Gozellix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home ASX

News & Views

Latest News

Category: ASX

See all

Telix Announces Record-Breaking Presence at EANM 2025

ASX, News,

Telix today announces its record-breaking conference presence with 28 company-related abstract presentations at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Barcelona from 4 – 8 October...

Read more

CMS Grants Transitional Pass-Through Status for Gozellix

ASX, News,

Telix today announces that the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide...

Read more

Telix and FDA Agree on Resubmission Pathway for TLX101-CDx (Pixclara®) U.S. NDA

ASX, News,

Telix today announces that it has reached agreement with the United States (U.S.) Food and Drug Administration (FDA) regarding resubmission of its New Drug Application (NDA) for TLX101-CDx (Floretyrosine F18...

Read more

Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth

ASX, News,

Telix today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August...

Read more

Telix H1 2025 Results: Investor Webcast Notification

ASX, News,

Telix today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August...

Read more

Telix Reports $204M Revenue, Up 63% YOY

ASX, News,

Telix today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated...

Read more

Gozellix Receives Permanent HCPCS Code

ASX, News,

Telix today announces that its next-generation PSMA PET imaging agent, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), has been granted a permanent Healthcare Common Procedure Coding System...

Read more

Telix at ANZSNM Annual Scientific Meeting 2025

ASX, News,

Read more

Telix’s Illuccix PSMA-PET Imaging Agent Approved in France

ASX, News,

Telix announces its Annual General Meeting of shareholders to be held...

Read more

AUA25: Telix to Showcase Urologic Pipeline at AUA: ProstACT Global, Illuccix® and Zircaix®

ASX, News,

Join Telix this week at the 2025 The American Urological Association (AUA) Annual Meeting in Las Vegas,...

Read more

Posts pagination

1 2 … 23

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”

Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings